The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades
| Autor: | Quinn T. Ostrom, Carol Kruchko, Jill S. Barnholtz-Sloan, Haley Gittleman, Christian Grommes, Joe S. Mendez, Lisa M. DeAngelis |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pediatrics Time Factors Adolescent Lymphoma Population Clinical Investigations Brain tumor Central Nervous System Neoplasms Young Adult 03 medical and health sciences 0302 clinical medicine Epidemiology Humans Medicine Registries Mortality Young adult Child education Survival rate Aged Aged 80 and over education.field_of_study business.industry Incidence Incidence (epidemiology) Age Factors Infant Newborn Primary central nervous system lymphoma Infant Middle Aged Prognosis medicine.disease United States Survival Rate Clinical trial Oncology Child Preschool 030220 oncology & carcinogenesis Immunology Female Neurology (clinical) business 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Neuro-Oncology. 20:687-694 |
| ISSN: | 1523-5866 1522-8517 |
| Popis: | BACKGROUND: There has been significant improvement in treatment outcomes of primary central nervous system lymphoma (PCNSL) at specialized centers over the past several decades; however, it is unclear if these changes have translated to benefits in the general population. METHODS: In this study, we utilized 2 national databases to examine survival trends over time for PCNSL: the Central Brain Tumor Registry of the United States (CBTRUS, 2000–2013) and 18 registries from the Surveillance, Epidemiology, and End Results program (SEER, 1973–2013). RESULTS: The annual incidence of PCNSL in 2013 was 0.4 per 100000 population (CBTRUS/SEER). Incidence increased from 0.1 per 100000 in the 1970s to 0.4 per 100000 in the 1980s, correlating with an increase in the diagnosis of patients ≥70 years (1973: 0.2 vs 2013: 2.1 [SEER]). Incidence rates differed greatly between young and elderly patients (age 20–29 y: 0.08 vs 70–79 y: 4.32 [CBTRUS]). Even though the median overall survival of all patients doubled from 12.5 months in the 1970s to 26 months in the 2010s, this survival benefit was limited to patients |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|